Narayana Health reported a 16% increase in Q4 profits, reaching ₹228 crore, although margins saw a decrease. The company is looking ahead to expanding operations in the Cayman Islands and has provided preliminary FY27 growth projections for further expansion.

Narayana Hrudayalaya's Q4 earnings show significant revenue increase, with the CFO attributing this to key growth factors.

Narayana Hrudayalaya reported a significant increase in Q4 EBITDA, reaching ₹7.55 billion compared to ₹3.85 billion last year. This boosted the EBITDA margin to 29.1%, up from 26.1% year-over-year, indicating improved profitability.

Narayana Hrudayalaya's Q4 revenue surged by 76% to ₹25,938 million due to robust growth across various locations. Despite this, the consolidated profit after tax increased by only 16%, reaching ₹2,283 million. The company's shares closed at ₹1,854.35, marking a slight drop from their previous trading price of ₹1,928.70.

Narayana Hrudayalaya has announced a ₹460 crore investment plan for upcoming projects in FY27. Notably, the structural work for their new South-West Bangalore facility is complete, with MEP and interior works currently underway.

Narayana Hrudayalaya, as announced, has fully utilized the Rs. 500 crore raised through Non-Convertible Debentures (NCD) by September 30, 2025, adhering to SEBI Regulation 52(7A). The funds were used as disclosed without any discrepancies.

Narayana Hrudayalaya, a leading player in the healthcare sector, demonstrates bullish tendencies, with a robust support level at ₹1800. The stock is projected to rise, aiming for a target price within the range of ₹1940-₹1950. Technical indicators such as RSI and moving averages point towards an optimistic trend, aligning with the current momentum in the healthcare sector.

HSBC has kept a cautious stance towards Narayana Hrudayalaya, setting a new price target at ₹1,630. The bank expects stability in Q4FY26, but mentions potential issues with elective procedures, capital expenditures, and margin pressure.